Moleculin Biotech (FRA:MOL) Current Accrued Expense : €2.94 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Moleculin Biotech Current Accrued Expense?

Moleculin Biotech's Current Accrued Expense for the quarter that ended in Mar. 2024 was €2.94 Mil.

Moleculin Biotech's quarterly Current Accrued Expense increased from Sep. 2023 (€1.76 Mil) to Dec. 2023 (€3.87 Mil) but then declined from Dec. 2023 (€3.87 Mil) to Mar. 2024 (€2.94 Mil).

Moleculin Biotech's annual Current Accrued Expense increased from Dec. 2021 (€1.91 Mil) to Dec. 2022 (€2.46 Mil) and increased from Dec. 2022 (€2.46 Mil) to Dec. 2023 (€3.87 Mil).

Moleculin Biotech Current Accrued Expense Historical Data

The historical data trend for Moleculin Biotech's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moleculin Biotech Current Accrued Expense Chart

Moleculin Biotech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

1.18

1.38

1.91

2.46

3.87

Moleculin Biotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															2.89	2.23	1.76	3.87	2.94

Moleculin Biotech Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Moleculin Biotech Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Moleculin Biotech's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Moleculin Biotech (FRA:MOL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moleculin Biotech Inc (FRA:MOL) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

MBRX:USA 0K2H:UK

Address

5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007

Website

https://www.moleculin.com

Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member.

Moleculin Biotech (FRA:MOL) Headlines

No Headlines